Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 13.78% and Operating profit at 9.56% over the last 5 years
- INTEREST(HY) At CNY 0.24 MM has Grown at 7.04%
- INTEREST COVERAGE RATIO(Q) Lowest at 27,898.96
- CASH AND EQV(HY) Lowest at CNY 361.15 MM
2
With ROE of 10.11%, it has a fair valuation with a 2.67 Price to Book Value
3
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-24.8%
0%
-24.8%
6 Months
-10.09%
0%
-10.09%
1 Year
37.8%
0%
37.8%
2 Years
-0.7%
0%
-0.7%
3 Years
-16.64%
0%
-16.64%
4 Years
-38.39%
0%
-38.39%
5 Years
-41.32%
0%
-41.32%
Cabio Biotech (Wuhan) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.78%
EBIT Growth (5y)
9.56%
EBIT to Interest (avg)
86.76
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
0.33
Tax Ratio
13.92%
Dividend Payout Ratio
27.15%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.13%
ROE (avg)
7.71%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
2.67
EV to EBIT
26.02
EV to EBITDA
18.87
EV to Capital Employed
2.91
EV to Sales
6.93
PEG Ratio
0.72
Dividend Yield
0.78%
ROCE (Latest)
11.17%
ROE (Latest)
10.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
121.30
150.80
-19.56%
Operating Profit (PBDIT) excl Other Income
22.30
79.60
-71.98%
Interest
0.40
0.60
-33.33%
Exceptional Items
-0.40
0.10
-500.00%
Consolidate Net Profit
20.50
62.00
-66.94%
Operating Profit Margin (Excl OI)
183.90%
427.50%
-24.36%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -19.56% vs -3.33% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -66.94% vs 39.64% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
553.70
440.70
25.64%
Operating Profit (PBDIT) excl Other Income
161.50
118.40
36.40%
Interest
0.60
0.80
-25.00%
Exceptional Items
0.30
-2.60
111.54%
Consolidate Net Profit
120.10
86.40
39.00%
Operating Profit Margin (Excl OI)
186.10%
155.00%
3.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.64% vs 2.30% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 39.00% vs 40.26% in Dec 2023
About Cabio Biotech (Wuhan) Co., Ltd. 
Cabio Biotech (Wuhan) Co., Ltd.
Specialty Chemicals
No Details Available.
Company Coordinates 
No Company Details Available






